Wall Street brokerages expect Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to announce $44.40 million in sales for the current quarter, according to Zacks. Two analysts have issued estimates for Vanda Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $43.80 million and the highest estimate coming in at $45.00 million. Vanda Pharmaceuticals posted sales of $38.48 million during the same quarter last year, which suggests a positive year over year growth rate of 15.4%. The firm is scheduled to announce its next earnings results on Wednesday, November 1st.

On average, analysts expect that Vanda Pharmaceuticals will report full year sales of $44.40 million for the current financial year, with estimates ranging from $168.70 million to $172.00 million. For the next year, analysts expect that the firm will report sales of $205.70 million per share, with estimates ranging from $194.00 million to $217.40 million. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover Vanda Pharmaceuticals.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.18. Vanda Pharmaceuticals had a negative net margin of 6.54% and a negative return on equity of 7.85%. The company had revenue of $42.06 million for the quarter, compared to analysts’ expectations of $40.31 million. During the same quarter in the previous year, the company earned $0.01 earnings per share. Vanda Pharmaceuticals’s quarterly revenue was up 16.7% on a year-over-year basis.

VNDA has been the topic of a number of research reports. Piper Jaffray Companies reissued an “overweight” rating and set a $23.00 target price on shares of Vanda Pharmaceuticals in a research report on Tuesday, June 27th. Zacks Investment Research downgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 18th. Oppenheimer Holdings, Inc. set a $21.00 target price on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 3rd. HC Wainwright set a $18.00 target price on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 3rd. Finally, BidaskClub downgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $21.29.

Several institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its position in shares of Vanda Pharmaceuticals by 7.5% in the 2nd quarter. Vanguard Group Inc. now owns 2,680,895 shares of the biopharmaceutical company’s stock worth $43,698,000 after buying an additional 186,548 shares during the last quarter. Point72 Asset Management L.P. grew its position in shares of Vanda Pharmaceuticals by 1,544.3% in the 1st quarter. Point72 Asset Management L.P. now owns 2,484,500 shares of the biopharmaceutical company’s stock worth $34,783,000 after buying an additional 2,333,400 shares during the last quarter. Macquarie Group Ltd. grew its position in shares of Vanda Pharmaceuticals by 8.8% in the 2nd quarter. Macquarie Group Ltd. now owns 1,703,559 shares of the biopharmaceutical company’s stock worth $27,768,000 after buying an additional 138,278 shares during the last quarter. State Street Corp grew its position in shares of Vanda Pharmaceuticals by 2.9% in the 2nd quarter. State Street Corp now owns 1,618,485 shares of the biopharmaceutical company’s stock worth $26,380,000 after buying an additional 46,299 shares during the last quarter. Finally, FMR LLC grew its position in shares of Vanda Pharmaceuticals by 60.7% in the 1st quarter. FMR LLC now owns 1,601,171 shares of the biopharmaceutical company’s stock worth $22,416,000 after buying an additional 604,900 shares during the last quarter. 86.49% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) traded down 1.79% during trading on Wednesday, hitting $16.50. 87,650 shares of the company traded hands. The company has a 50 day moving average price of $17.45 and a 200 day moving average price of $15.62. Vanda Pharmaceuticals has a 52 week low of $12.70 and a 52 week high of $18.99. The company’s market capitalization is $740.16 million.

COPYRIGHT VIOLATION NOTICE: “Brokerages Anticipate Vanda Pharmaceuticals Inc. (VNDA) Will Announce Quarterly Sales of $44.40 Million” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/11/brokerages-anticipate-vanda-pharmaceuticals-inc-vnda-will-announce-quarterly-sales-of-44-40-million.html.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Get a free copy of the Zacks research report on Vanda Pharmaceuticals (VNDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.